# Geographic spillover of antimicrobial resistance from mass distribution of azithromycin

**Authors:** Ariktha Srivathsan, Ahmed M. Arzika, Ramatou Maliki, Amza Abdou, Marc Lipsitch, Seth Blumberg, Kieran S. O’Brien, Travis C. Porco, Armin Hinterwirth, Thuy Doan, Jeremy D. Keenan, Thomas M. Lietman, Benjamin F. Arnold

PMC · DOI: 10.1038/s41467-026-68691-y · Nature Communications · 2026-01-29

## TL;DR

A study in Niger found no evidence that antibiotic resistance spread from villages where children received azithromycin to nearby untreated villages.

## Contribution

The study provides evidence that antimicrobial resistance from azithromycin MDA does not spill over to untreated areas.

## Key findings

- No geographic spillover of macrolide resistance was detected in untreated villages.
- Resistance gene abundance remained at baseline levels regardless of surrounding treatment intensity.
- Sensitivity analyses confirmed no spillover for other antibiotic classes.

## Abstract

Large-scale, placebo-controlled, cluster-randomized trials in high-mortality settings in sub-Saharan Africa demonstrated a 14–18% reduction in childhood mortality following twice-annual mass drug administration (MDA) of azithromycin among children aged 1–59 months. Azithromycin MDA also selected for antimicrobial resistance (AMR), particularly macrolide resistance. It is unknown whether the AMR from azithromycin MDA could spill over to neighboring untreated populations. If present, such geographic spillover effects could lead trials to underestimate AMR risks. We assess between-village geographic spillover effects of genotypic macrolide resistance using metagenomic deep sequencing in rectal swabs collected from 300 children in 30 monitoring villages in Niger after two years of MDA in 594 surrounding villages. Conditional permutation tests assess associations between proximal azithromycin treatment intensity and resistance gene abundance. We find no evidence of geographic spillover of macrolide resistance in untreated villages, as the genetic load of AMR remains at baseline levels in placebo-treated villages regardless of surrounding azithromycin treatment intensity (Spearman ρ = −0.05, P = 0.83). Sensitivity analyses confirm robustness across metrics, and no spillover effects are detected for other antibiotic classes. Azithromycin MDA-induced macrolide resistance appears localized to treated villages, mitigating some concerns about geographic spillover of AMR to nearby untreated villages at 24 months.

After two years of mass azithromycin distribution to preschool age children in rural Niger, in this study, authors present evidence that selection of antibiotic resistance genes was not spread from treated villages to nearby untreated villages.

## Linked entities

- **Chemicals:** azithromycin (PubChem CID 447043)

## Full-text entities

- **Chemicals:** Azithromycin (MESH:D017963), macrolide (MESH:D018942)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12957345/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12957345/full.md

## References

8 references — full list in the complete paper: https://tomesphere.com/paper/PMC12957345/full.md

---
Source: https://tomesphere.com/paper/PMC12957345